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Background: Microbial biofilms have been associated with the development of chronic human infections and
represent a clinical challenge given their increased antimicrobial tolerance. Staphylococcus aureus is a major human
pathogen causing a diverse range of diseases, of which biofilms are often involved. Staphylococcal attachment and
the formation of biofilms have been shown to be facilitated by host factors that accumulate on surfaces. To better
understand how host factors enhance staphylococcal biofilm formation, we evaluated the effect of whole human
plasma on biofilm formation in clinical isolates of S. aureus and the expression of seven microbial surface components
recognizing adhesive matrix molecules (MSCRAMMs) known to be involved in biofilm formation by quantitative
real-time PCR. We also evaluated whether plasma augmented changes in S. aureus biofilm morphology and
antimicrobial resistance.
Results: Exposure of clinical isolates of S. aureus to human plasma (10%) within media, and to a lesser extent when
coated onto plates, significantly enhanced biofilm formation in all of the clinical isolates tested. Compared to biofilms
grown under non-supplemented conditions, plasma-augmented biofilms displayed significant changes in both the
biofilm phenotype and cell morphology as determined by confocal scanning laser microscopy (CLSM) and scanning
electron microscopy (SEM), respectively. Exposure of bacteria to plasma resulted in a significant fold-increase in
MSCRAMM expression in both a time and isolate-dependent manner. Additionally, plasma-augmented biofilms
displayed an increased tolerance to vancomycin compared to biofilms grown in non-supplemented media.
Conclusions: Collectively, these studies support previous findings demonstrating a role for host factors in biofilm
formation and provide further insight into how plasma, a preferred growth medium for staphylococcal biofilm
formation enhances as well as augments other intrinsic properties of S. aureus biofilms. Consequently, these findings
indicate that incorporation of host factors may be necessary to better replicate in vivo conditions and for the best utility
of a clinical biofilm assay to evaluate the process of biofilm formation and treatments.
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Staphylococcus aureus is a significant human pathogen
that causes a wide range of infections. The ability of
S. aureus to colonize and establish biofilms, a surface-
attached microbial community surrounded by a self-
produced polymeric matrix, is a central pathogenic
event contributing to disease in humans [1]. Biofilms
are implicated as a significant factor contributing to
chronic human infections [2-4], and represent a major
challenge to modern medicine given their recalcitrance
to antimicrobials and host mechanisms of clearance. Bio-
film formation is a complex process involving distinct
phases of attachment, accumulation, and maturation.
The attachment of staphylococci and subsequently the
accumulation phases of biofilm development are pre-
dominantly mediated by different types of bacterial
adhesins. More specifically, a class of surface proteins
known as the microbial surface components recogniz-
ing adhesive matrix molecules (MSCRAMMs), which
in addition to virulence, are responsible for mediating
initial attachment to both naïve tissues and various bio-
materials [5-7].
Data continues to accumulate regarding S. aureus bio-
film formation, but there is increasing evidence that
in vitro biofilm assays may not accurately represent
in vivo biofilms [8]. Factors potentially causing discrep-
ancies between in vivo and in vitro conditions include
the presence of host proteins, of which human plasma is
the best characterized [5-9]. Plasma is a major compo-
nent of blood [normally approximating 55%, volume/
volume (v/v)] and is composed of coagulation factors, al-
bumin, globulins and other factors [9-11]. Most body
fluids consist of plasma filtrates and proteins present in
plasma are also found at varying concentrations in hu-
man body fluids, to include (percent, v/v): burn wound
exudates (10-44%), acute soft tissue wound exudates
(23-36%), interstitial fluid (10-27%), nasal secretions
(15-45%), ascitic fluid (4-26%), lymphatic fluid (10-50%),
and synovial fluid (1-73%) [12-17]. The importance of host
proteins in facilitating biofilm formation is highlighted by
studies demonstrating that medical implants are often
coated by various host matrix proteins, serving to enhance
bacterial attachment and biofilm formation in vivo [7,8] as
well as in vitro where the use of plasma has been shown
to promote biofilm growth [18,19].
To better understand how host factors, in particular
those within human plasma, augment biofilm formation
in S. aureus, herein we examined the effect of human
plasma on biofilm formation in clinical isolates, and
evaluated its effects on the expression of staphylo-
coccal MSCRAMMs important to biofilm formation.
Furthermore, we also evaluated the effects of plasma on
biofilm/bacterial morphology and changes in resistance to
antimicrobials.Results and discussion
Human plasma enhances biofilm formation by clinical
isolates of S. aureus, in part through increased MSCRAMM
expression
Previous studies have shown that supplementing media,
as well as coating surfaces, with human plasma can fa-
cilitate S. aureus attachment and promote biofilm accu-
mulation in vitro [18,19]. Consistent with these studies,
supplementation of media with plasma, and to a much
lesser extent when used to coat plates, was observed to
enhance biofilm formation for all of the clinical iso-
lates tested herein (Table 1). Interestingly, analysis of
staphylococcal biofilms by CLSM, also demonstrated
that the biofilm phenotype was altered in the presence of
human plasma, however changes in phenotype were
strain dependent. For S. aureus MRSA3, the addition of
plasma significantly enhanced biomass accumulation,
whereas for S. aureus UAMS-1 the effect of plasma on
biofilm formation seemed to be related to morphology,
appearing more dense and compact compared to biofilms
grown in only media (Figure 1A-B). Although coating of
plates with 20% plasma v/v was previously reported to
be optimal for promoting biofilm formation on glass
coverslips, we observed that coating had a minimal ef-
fect on biofilm formation by the clinical isolates even at
concentrations >5% v/v [19]. In contrast to these studies,
and consistent with recent studies described in Chen
et al., supplementation of media with plasma between
10-25% v/v was observed to be a more optimal biofilm
growth condition, significantly enhancing biofilm forma-
tion compared to biofilms grown under non-supplemented
conditions or in wells coated with plasma at similar con-
centrations (Table 1) [18]. Notably, the effect of plasma on
biofilm formation was isolate-dependent, with methicillin-
resistant isolates appearing more responsive to plasma than
the methicillin-susceptible isolate, UAMS-1 (Table 2).
The observed variability of biofilm formation in re-
sponse to plasma among the S. aureus isolates is not
surprising, and likely indicates differences in genetic
backgrounds and consequently in the binding affinity to
plasma components, such as fibrinogen and fibronectin
[20-22]. Indeed, as the coating of surfaces with plasma is
thought to provide surface attachments, the differences
in gene repertoire as well as expression can in part ex-
plain these observed differences. Importantly, the obser-
vation that supplementing media with plasma, rather
than coating the surface, had a greater effect on biofilm
formation suggests that the components of plasma may
not only serve to facilitate attachment as previously
thought, but may also impart changes to bacteria making
them better suited for biofilm growth. In support of this,
SEM analysis of biofilms grown with media supple-
mented with plasma demonstrated significant changes in
the cell morphology of individual bacterial cells within
Table 1 S. aureus biofilm formation is more enhanced
when plasma is part of the growth medium, compared to














1 0.81±0.41 1.63±0.48 0.15
5 0.56±0.33 1.4±0.58 0.17
10 0.25±0.08 2.4±0.46 0.01
25 0.3±0.2 1.95±0.58 0.02
50 0.32±0.17 0.83±0.76 0.22
MRSA 1
0 0.36±0.13 0.38±0.18
1 0.28±0.06 0.77±0.26 0.06
5 0.67±0.47 1.08±0.49 0.22
10 0.56±0.44 1.44±0.33 0.03
25 0.58±0.27 1.22±0.3 0.08
50 0.38±0.21 0.67±0.56 0.33
MRSA 2
0 0.38 + 0.13 0.6 ± 0.19
1 0.57 + 0.02 2.26 + 0.17 0.04
5 0.79 + 0.47 2.37 + 0.1 0.04
10 0.7 + 0.58 2.82 + 0.04 0.03
25 0.67 + 0.49 2.47 + 0.6 0.04
50 0.5 + 0.25 1.3 + 0.99 0.24
MRSA 3
0 0.58 + 0.31 0.53 ± 0.14
1 0.5 + 0.07 2.46 + 0.57 0.04
5 0.93 + 0.69 2.26 + 0.71 0.11
10 0.63 + 0.16 2.18 + 0.68 0.04
25 0.53 + 0.51 2.5 + 0.37 0.02
50 0.36 + 0.16 1.84 + 1.0 0.14
*96-well plates were coated with plasma for 24 hours, washed then biofilm
was formed.
‡Plasma coated compared to plasma in the growth medium. P-values generated
via One-way ANOVA with a Dunnett’s post hoc test.
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more heterogeneous appearing cell wall (Figure 1C-D).
These changes to morphology, and likely to other prop-
erties of the biofilm, highlight the multiple effects that
plasma can have in addition to the observed increases in
biomass.
Although the effects of plasma have been previously
reported, it is not completely understood how plasma
enhances staphylococcal biofilm formation [7,18,19].
Staphylococci possess a number of surface expressedadhesins known as MSCRAMMs that facilitate attachment
to host matrix molecules and are important for biofilm
formation [5,6]. As these ligands are responsible for
mediating attachment to surfaces, through interactions
with host matrix components, we evaluated the effect
of plasma on the expression of seven MSCRAMMs, in-
cluding laminin binding protein (eno), encoding elastin
binding protein (ebps), fibrinogen binding protein (fib),
clumping factor A/B (clfa/clfb), and fibronectin binding
protein A/B (fbnA/fbnB) following exposure to plasma.
In response to plasma, significant changes in MSCRAMM
gene expression were observed for all clinical isolates
tested (Table 3). The effect of plasma on MSCRAMM gene
expression was both isolate- and time-dependent. Of the
genes evaluated, expression of the fibrinogen and fibronec-
tin binding protein genes were most responsive to plasma
exposure (Table 3).
The transition from planktonic to surface-attached
growth results in significant changes in gene expression
that may promote the biofilm mode of growth. Consistent
with our observations, gene expression of MSCRAMMs
during biofilm growth, including fnbA/B, clfa, ebps, and
fib, have also been shown to be significantly enhanced dur-
ing biofilm growth [23]. However, in these studies the ex-
pression of MSCRAMMs was optimally enhanced between
12 and 24 hours of biofilm growth. In contrast, we ob-
served significant expression of the various MSCRAMM
genes (>3 fold) after only 30 minutes following plasma
exposure. This supports previous findings by Chen et al.
demonstrating significant increases in biofilm biomass as
early as six hours of growth compared to biofilms grown
under normal conditions [18] and indicating that plasma
enhanced biofilm formation may in part result from
changes in gene expression of MSCRAMMs.
Biofilms grown in the presence of plasma demonstrate
increased tolerance to vancomycin in vitro
Given the findings demonstrating the effects of plasma
on bacterial gene expression and morphology, we next
evaluated whether plasma augmentation of biofilms also
had an effect on the susceptibilities of biofilms to anti-
microbials using a well-described biofilm susceptibility
assay [24]. In contrast to biofilms grown without plasma,
biofilms grown in the presence of plasma demonstrated
a significantly reduced susceptibility to vancomycin in vitro
(Figure 2). Consistent with this, plasma augmented bio-
films of a clinical methicillin resistant (MRSA3) and methi-
cillin susceptible S. aureus (UAMS-1) isolate had greater
numbers of viable bacteria, as determined by colony enu-
meration, following overnight exposure to vancomycin
even at the highest concentrations tested compared to
untreated controls (Figure 2A-B). In agreement with these
results, SEM analysis of biofilms grown in the presence
of plasma following exposure to vancomycin at similar
Figure 1 Visualization of staphylococcal biofilms grown in the presence of human plasma by CLSM and SEM. A-B) CLSM images biofilms
of a methicillin-resistant (MRSA-3) and methicillin susceptible (UAMS-1) isolates of S. aureus grown overnight on coverslips in media supplemented
with or without human plasma (10% Plasma). Biofilms were stained with a bacterial and a biofilm matrix stain to visualize the bacterial cells and
extracellular polymeric matrix, respectively. Images were captured at 20X magnification. C-D) SEM analysis of biofilms of the clinical isolates listed
above, following exposure to human plasma. Images were captured at 40,000X. Inlayed size bars represent 200 nm.
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tached, viable bacteria (Figure 2C-D).
One possible explanation for the observed increased
resistance to vancomycin, could involve selection for
persister cells [25]. Recent data in Staphylococcus epider-
midis suggests that the number of persister cells, bac-
teria within the biofilm having low metabolic activity
and accounting for the population resistant to antimi-
crobials, increases at high bacterial densities [26]. Al-
though we did not assess for the presence of persister
cells, plasma-augmentation was observed to increase
bacterial density and by extension may have increased theTable 2 Increase in biofilm biomass measured by Crystal Viol
UAMS-1 MRSA-1
OD570±SD %±SD OD570±SD %±SDs
0% 0.87±0.31 N/A 0.38±0.18 N/A
1% 1.63±0.48 87±29 0.77±0.26 102±34
5% 1.40±0.58 61±41 1.08±0.49* 189±45ϯ
10% 2.40±0.46 171±19 1.44±0.33* 279±23ϯ
25% 1.95±0.58 124±30 1.22±0.30* 221±25ϯ
50% 0.83±0.76 −5±92 0.67±0.56 76±84
*P ≤ 0.05 vs. 0% plasma, One-way ANOVA with Dunnet’s post hoc test.
ϯP ≤ 0.05 Percent increase in biofilm biomass (UAMS-1 vs. MRSA-1, MRSA-2, or MRS
hoc test.
Results are expressed as Mean OD570 ± standard deviation and percent change fronumber of persister cells within the biofilm. Alternately,
the inoculum effect may also explain why plasma-
augmented biofilms displayed reduced vancomycin sus-
ceptibility, as plasma-augmentation resulted in 3 log-units
higher inoculum in the biofilms. Interestingly, vancomycin
resistance in S. aureus has also been associated with in-
creased cell wall thickness [27]. Given our observation by
SEM that plasma treatment altered the S. aureus cell sur-
face morphology (Figure 1, C-D), cell wall alteration may
also have contributed to the overall reduced vancomycin
susceptibility noted in this study. Nonetheless, the finding
of reduced vancomycin susceptibility in plasma-exposedet method following incubation in plasma
MRSA-2 MRSA-3
OD570±SD %±SD OD570±SD %±SD
0.6 ± 0.19 N/A 0.53 ± 0.14 N/A
2.26 ± 0.17* 277 ± 8ϯ 2.46 ± 0.57* 364 ± 23ϯ
2.37 ± 0.1* 295 ± 4ϯ 2.26 ± 0.71* 326 ± 31ϯ
2.82 ± 0.04* 370 ± 1ϯ 2.18 ± 0.68* 311 ± 31ϯ
2.47 ± 0.60* 317 ± 24ϯ 2.50 ± 0.37* 368 ± 15ϯ
1.30 ± 0.99 117 ± 76 1.84 ± 1.0 249 ± 54ϯ
A-3) at comparable plasma percentages, One-way ANOVA with Dunnet’s post
m 0% plasma ± SD.
Table 3 10% Plasma alters MSCRAMM gene expression in a strain dependent fashion
Strain Gene Fold increase in gene expression*
30 min 60 min 90 min 120 min
UAMS-1 Laminin binding protein (Eno) 1.62 2.06 2.76 3.39
Encoding elastin binding protein (ebps) 3.42 2.98 4.61 3.50
Fibrinogen binding protein (fib) 0.00 17.12 32.52 30.86
Clumping factor A (clfA) 2.08 3.57 6.03 4.43
Clumping factor B (clfB) 1.04 5.48 2.33 4.39
Fibronectin binding protein (fbnA) 11.22 4.28 5.25 1.96
Fibronectin binding protein (fbnB) 5.53 4.71 4.76 3.02
MRSA-1 Laminin binding protein (Eno) 1.51 2.15 2.85 2.51
Encoding elastin binding protein (ebps) 1.11 1.29 2.02 1.75
Fibrinogen binding protein (fib) 5.18 7.88 13.92 7.86
Clumping factor A (clfA) 2.88 2.82 3.69 4.10
Clumping factor B (clfB) 0.98 1.62 2.73 2.32
Fibronectin binding protein (fbnA) 32.23 46.84 30.30 2.79
Fibronectin binding protein (fbnB) 0.87 13.97 5.14 5.36
MRSA-2 Laminin binding protein (Eno) 1.06 3.53 3.83 3.63
Encoding elastin binding protein (ebps) 1.01 3.80 2.12 1.38
Fibrinogen binding protein (fib) 1.30 4.16 6.21 3.14
Clumping factor A (clfA) 4.08 3.13 3.90 2.62
Clumping factor B (clfB) 1.14 1.60 2.50 3.91
Fibronectin binding protein (fbnA) 2.59 7.14 4.89 2.00
Fibronectin binding protein (fbnB) 3.62 3.72 3.31 2.61
MRSA-3 Laminin binding protein (Eno) 1.31 1.86 3.96 2.95
Encoding elastin binding protein (ebps) 0.99 1.21 3.67 1.88
Fibrinogen binding protein (fib) 2.44 6.92 5.18 3.49
Clumping factor A (clfA) 1.82 1.73 5.56 2.73
Clumping factor B (clfB) 1.32 1.15 3.78 3.22
Fibronectin binding protein (fbnA) 2.57 2.08 4.26 5.30
Fibronectin binding protein (fbnB) 2.60 2.35 3.53 3.75
*A greater than or equal to 3 fold increase was statistically significant (p<0.05) compared to baseline gene expression (t=0), and are indicated in boldface, One-way ANOVA
with a Dunnet’s post hoc test.
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of antimicrobials and novel treatments against biofilms
in vitro. Based on these studies, the inclusion of host fac-
tors may be necessary to fully evaluate susceptibility of
biofilm-associated organisms under conditions that simu-
late the in vivo environment.
Conclusion
Most in vitro models used to study biofilms utilize incu-
bation periods ranging from 12 to 48 hours, varying
concentrations of ambient oxygen and carbon dioxide dur-
ing incubation, varying incubation temperatures, and often
omit potentially important host factors [8,28,29]. Conse-
quently, although useful for high throughput analysis,
in vitro models may not represent the true capacity ofpathogens to form biofilms in vivo [8,28,29]. Thus there is
a need for standardization in biofilm testing methods
which is currently lacking [8].
While plasma has been previously demonstrated to
increase biofilm formation [5-9,18,19], our study has
extended this observation by examining the impact of
plasma on several clinical isolates, demonstrating that
host factors, including human plasma, can influence cell
morphology and S. aureus gene expression, which may
favor the biofilm phenotype.
These findings indicate a role for inclusion of host
components into models evaluating biofilm formation as
it would be more representative of in vivo conditions
and may more accurately facilitate clinically relevant bio-
film studies.
Figure 2 Plasma augmented biofilms have reduced susceptibility to vancomycin in vitro. A-B) Viability of bacteria (Log10 CFU/mL) within
plasma augmented (MHB-10% Plasma, light bars) and non-augmented (MHB, dark bars) biofilms of a methicillin resistant (MRSA 3) and methicillin
susceptible (UAMS-1) strain of S. aureus following overnight exposure to vancomycin (0, 2, 16, 128, and 1024 μg/mL). Bar graphs are indicative
of the mean bacterial CFU ± SD. P-values generated via One-way ANOVA with a Dunnett’s post hoc test. C-D) SEM analysis of plasma and
non-plasma augmented biofilms from the isolates listed above, following exposure to vancomycin. Images were captured at 2,500X. Size bars
represent 10 μm.
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Bacterial isolates and growth conditions
Three clinical methicillin-resistant S. aureus (MRSA)
isolates collected during clinical care from inpatients at our
facility, previously demonstrated to be strong biofilm-
formers, were selected for study [30]. UAMS-1 (ATCC
49230), is a well-characterized, methicillin-susceptible
osteomyelitis isolate of S. aureus [31]. The other isolates in
this study were isolated from the following anatomic sites:
bone (UAMS-1), nares (MRSA-1, MRSA-3), and the tra-
chea (MRSA-2). The isolates also represent a variety of
pulsed-field gel electrophoresis types: USA100 (MRSA-1),
USA200 (UAMS-1), USA300 (MRSA-3), and USA800
(MRSA-2). Bacterial cultures were maintained at −80°C
and sub-cultured on sheep’s blood agar plates (Remel,
Lenexa, KS, USA) overnight at 37°C prior to each experi-
mental assay. Bacteria were grown in Cation-Adjusted
Mueller-Hinton Broth (MHB) (Becton Dickinson, FranklinLakes, NJ). UAMS-1 and MRSA-3 were selected for
CLSM, SEM, and antimicrobial susceptibility testing.
Antimicrobial agents and reagents
Human plasma was purchased from the Biological Spe-
cialty Corporation (Colmar, PA). Plasma was filtered
using 100 μm cell isolators (BD Falcon, Franklin Lakes,
NJ) and diluted in MHB at 1, 5, 10, 25, and 50% (v/v).
Vancomycin powder was purchased from Sigma-Aldrich
(St Louis, MO).
Biofilm formation in 96-well microtiter plates
Biofilm formation was assessed by measuring the accumu-
lation of biomass in sterile 96-well flat-bottom polystyrene
plates (Costar, Corning Incorporated, Lowell MA) as previ-
ously described following 24 h incubation [30]. Briefly,
10 μL of overnight bacterial suspensions (~108 CFU) were
added to wells containing 190 μL media supplemented
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plasma. Following 24 h incubation at 37°C, wells were
washed with PBS, stained with 0.1% crystal violet, and bio-
mass was quantified by measuring the optical density at
570 nm (OD570) of the supernatant following solubilization
in ethanol. All experiments were performed in triplicate.
Confocal laser scanning microscopy (CLSM)
Biofilm formation by select clinical isolates was carried
out on glass chamber slides (Thermo Scientific-Nunc,
Rochester, NY) following 24 h exposure to media with
or without 10% plasma by CLSM as previously described
[19]. Briefly, following biofilm growth cells were washed
with PBS and fixed with 4% formaldehyde. Biofilms
were stained with a biofilm cell stain to visualize the
extracellular polymeric matrix and bacterial cells ac-
cording to the manufacturer’s instructions (Molecular
Probes, Eugene, OR). CLSM images were acquired using
an Olympus FluoView 1000 Laser Scanning Confocal
Microscope (Olympus America Inc., Melville, NY) under
20X magnifications using an argon laser at 488 nm and a
HeNe-G laser at 543 nm. Image analysis/processing were
via Olympus FluoView software. Images were acquired
from at least three distinct regions on the slide and repre-
sentative images were selected.
Scanning electron microscopy (SEM)
Biofilm formation was carried out for 24 h as described
above in the presence or absence of 10% plasma, using
the MBEC™ P&G from Innovotech (Edmonton, Alberta,
Canada). Following incubation, individual pegs were re-
moved and fixed with 2% (w/v) gluteraldehyde, 2% (w/v)
paraformaldehyde, 0.15 M sodium cacodylate, 0.15% (w/v)
alcian blue. Pegs were rinsed thrice with 0.15 M sodium
cacodylate buffer, immersed in 1% (v/v) osmium tetroxide
in sodium cacodylate buffer and incubated for 1 hr at room
temperature. Pegs were rinsed thrice with distilled water
followed by dehydration with an ascending series of
ethanol (50%, 75%, 95%, and 100%). Samples were treated
with hexamethyldisilizane for 5 minutes, re-submerged
and allowed to evaporate at room temperature prior to
mounting. Copper tape was used to secure the pegs to car-
bon tape on stubs to reduce charging artifact. Samples
were sputter coated with gold and viewed with a Zeiss
SigmaVP scanning transmission electron microscope.
RNA isolation and quantitative real time reverse
transcription PCR (qRT-PCR)
Bacteria were grown to an OD600 of 0.2 (~10
8 bacteria/ml),
washed with 1X PBS, and added to MHB media sup-
plemented with 10% human plasma at a final concen-
tration of 2 x 108 CFU/mL. Bacteria were incubated
in MHB with 10% (v/v) plasma for 0, 30, 60, 90, and
120 min at 37°C. Time points were chosen based onprevious studies determined to be optimal for evaluat-
ing expression of MSCRAMMs following exposure to
host components [32]. In addition, these time-points were
chosen as the exopolysaccharide of the developing biofilm
is visible in just 5 hours after inoculation and has the char-
acteristics of a mature biofilm by 10 hours have been, and
if plasma were to enhance biofilm formation via increased
MSCRAMM expression, gene expression favoring bio-
film formation would be induced in planktonic bac-
teria soon after exposure, prior to biofilm formation and
maturation [33].
At the indicated timepoints, bacteria were harvested
by centrifugation, washed, and RNA was isolated using
an RNeasy Mini Kit (Qiagen, Valencia, CA) combined
with Bacterial-RNA Protect (Qiagen) following the man-
ufacturer’s instructions. Bacteria were lysed by treating
cells with lysostaphin (200 μg/ml) (Sigma-Aldrich, St.
Louis, MO) for 30 min at 37°C (30). RNA was isolated,
and reverse transcribed using the High Capacity cDNA
reverse transcription kit (Life Technologies, Grand
Island, NY), per the manufacturers’ protocol. Quantitation
of gene expression was via TaqMan (Life Technologies)
methodology using the relative standard curve method.
The gene specific PCR primers were developed with
Primer Express software (Life Technologies) (Table 1).
Gyrase B expression was the endogenous control. Real-
time quantitative PCR reactions were performed with
1.5 ng of total RNA converted to cDNA template. PCR re-
actions consisted of the cDNA template, 1X Universal
PCR Master Mix for Gene Expression (Life Technologies),
gene specific primers (900 nM) and probe (250 nM) in a
total volume of 20 μL. Standard curves consisted of ten-
fold dilutions of a positive control sample. PCR reactions
were performed in triplicate and cycled in a 7900HT
Sequence Detection System using standard protocols
(Applied Biosystems, Grand Island, NY). Transcript levels
were normalized to the internal control mRNA and fold-
regulation changes was calculated using 2–ΔΔCt method.
Fold-gene expression equal or greater than 3-fold was de-
termined to be statistically significant (p < 0.05), following
analysis using a 1-way ANOVA with a Dunnett’s post hoc
test comparing treatment groups to the control group.
Viability of biofilm-derived bacteria after vancomycin
exposure
Biofilm formation was carried out as described above
using the MBEC™ P&G. Briefly, bacteria were inoculated
into wells containing either MHB with or without
plasma (10%), covered with a lid containing pegs for the
attachment of the bacteria, and incubated at 37 ºC for
24 hr with agitation. Following incubation, plate lids
containing the pegs with the attached biofilms were
washed with PBS, placed into 96 well plates containing
2-fold serial dilutions of antibiotics diluted in MHB, and
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of biofilm-derived bacteria following vancomycin expos-
ure, MBEC plate lids were washed, placed into 96-well
plates containing MHB, and biofilm-derived bacteria were
detached from the pegs of lids by sonication for 5 min.
Plate lids with pegs were removed and replaced with a con-
ventional microtiter plate lid. Bacterial viability was deter-
mined by plating serial dilutions on blood agar plates at 0,
and 6 hours post-exposure as per a previous study [34].
Statistical analysis
All experiments were performed in triplicate with a
minimum of three technical replicates per individual ex-
periment. The data sets were normally distributed, and
for all quantitative studies a One-way ANOVA with a
Dunnett’s post hoc test was used to compare all treat-
ment groups to the control group. P-values of ≤0.05
were considered to be statistically significant. Statistical
software utilized was SigmaStat® Version 12.0.
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